Pharmaceutical News

RSS

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

The District of Columbia Department of Health has released a study by the George Washington University School of Public Health and Health Services investigating prescribing of antipsychotics to District seniors.

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Adolescents vaccination for pertussis linked with lower rates of infant hospitalizations

Widespread vaccination of adolescents for pertussis was associated with lower rates of infant hospitalizations for the respiratory infection than would have been expected had teens not been inoculated according to new research in Pediatrics.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.

19 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).

19 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

18 Oct 2013

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Suspicions about sexual promiscuity and vaccine safety are explored in an article in the November issue of the journal Preventive Medicine, which dedicates a section of that issue to research concerning the human papillomavirus.

18 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

Study finds no relevant association between Vitamin D serum level and incidence of kidney stones

Increased vitamin D levels may prevent a wide range of diseases, according to recent studies. However, some previous studies led to a concern that vitamin D supplementation could increase an individual's risk of developing kidney stones.

18 Oct 2013

Use of effective, risky drug therapies by Medicare patients varies across US

A new report from the Dartmouth Atlas Project shows that the use of both effective and risky drug therapies by Medicare patients varies widely across U.S. regions, offering further evidence that location is a key determinant in the quality and cost of the medical care that patients receive.

18 Oct 2013

Pharmaceutical News

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

New investigational drug offers potential treatment option for lung cancer

Adolescents vaccination for pertussis linked with lower rates of infant hospitalizations

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Study finds no relevant association between Vitamin D serum level and incidence of kidney stones

Use of effective, risky drug therapies by Medicare patients varies across US

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News